Cell line killing based on MS evidence of HLA-A*02:ALNEQIARL
| Cell line . | HLA-A*02/MS . | NDC80-clC killing . | NDC80-clE killing . |
|---|---|---|---|
| Hematologic malignancies | |||
| AML14 | +/+ | +++ | + |
| OCI-AML02 | +/+ | +++ | + |
| BV173 | +/+ | +++ | + |
| SUDHL6 | +/+ | + | − |
| MAC2A | +/+ | +++ | + |
| SUDHL4 | +/− | − | − |
| HL60 | −/− | − | − |
| Nonhematologic malignancies | |||
| JMN | +/+ | +++ | + |
| TPC-1 | +/+ | ++ | − |
| MDA-MB231 | +/+ | ++ | − |
| PANC-1 | +/+ | + | − |
| SKMEL-5 | +/+ | + | − |
| HCT116 | +/− | − | − |
| T47D | −/− | − | − |
| Cell line . | HLA-A*02/MS . | NDC80-clC killing . | NDC80-clE killing . |
|---|---|---|---|
| Hematologic malignancies | |||
| AML14 | +/+ | +++ | + |
| OCI-AML02 | +/+ | +++ | + |
| BV173 | +/+ | +++ | + |
| SUDHL6 | +/+ | + | − |
| MAC2A | +/+ | +++ | + |
| SUDHL4 | +/− | − | − |
| HL60 | −/− | − | − |
| Nonhematologic malignancies | |||
| JMN | +/+ | +++ | + |
| TPC-1 | +/+ | ++ | − |
| MDA-MB231 | +/+ | ++ | − |
| PANC-1 | +/+ | + | − |
| SKMEL-5 | +/+ | + | − |
| HCT116 | +/− | − | − |
| T47D | −/− | − | − |